Drugs for Neglected Diseases initiative (DNDi)

See the following -

Africa: Partners Commit To Bolster Open Source Research

Press Release | Medicines for Malaria Venture (MMV), Drugs for Neglected Diseases initiative (DNDi), Royal Society of Chemistry (RSC) | November 27, 2013

The Royal Society of Chemistry (RSC), UK, Drugs for Neglected Diseases initiative (DNDi) and MMV have signed a memorandum of understanding (MoU) to collaborate in an effort to build a global community of researchers contributing to open source drug discovery for diseases of poverty. Read More »

Funding Crunch Hits Neglected Diseases Plan

Staff Writer | SciDev.Net | April 29, 2014

The Open Source Drug Discovery (OSDD) programme — a global collaborative initiative supported by the Indian government to find affordable treatment for neglected tropical diseases — has suffered a temporary setback due to a funds crunch caused by tardy submission of funding estimates. Read More »

Less Neglect, More Openness: Two ‘Grand Experiments’ In Health Innovation

Bernard Pécoul | PLOS.org | November 28, 2013

Commemorating the 10th Anniversaries of PLOS and the Drugs for Neglected Diseases initiative (DNDi), Bernard Pécoul, Executive Director of DNDi, discusses the innovative journeys of the organisations. Read More »

Major Patent Pool Opens Up Research On Neglected Disease

Yojana Sharma | SciDev.Net | October 31, 2011

Research on drug development for neglected tropical diseases (NTDs), tuberculosis and malaria will receive a boost from a major initiative launched by the World Intellectual Property Organization (WIPO) last week (26 October). Read More »

Mycetoma: The Untold Global Health Story of 2015

Brian W. Simpson | Global Health NOW | December 7, 2015

“It is unjust that people don’t care about this disease.” Writer Amy Maxmen’s words keep surfacing in my thoughts. She said this after her trip to Sudan to report on mycetoma, a flesh-eating, bone-destroying disease that spreads misery across 23 countries from Mexico to India. Although it’s exacted a horrific toll on human lives for centuries, very little is known about its prevalence or etiology. Bacterial or fungal in origin, the disease starts with a skin infection that over time grotesquely swells feet and other appendages. It erupts in painful lesions on the skin even as it destroys the bones within. Often the only treatment is amputation. Sometimes the disease proves fatal...

Read More »

New Open Source Drug Discovery Project Aims to Develop Mycetoma Treatment

Press Release | ErasmusMC , University of Sydney , DNDi | February 6, 2018

The MycetOS (Mycetoma Open Source) project was launched today by the University of Sydney, Erasmus MC, and the Drugs for Neglected Diseases initiative (DNDi) to use an Open Pharma approach to discover compounds that could lead to new treatments for patients suffering from fungal mycetoma (eumycetoma), a devastating disease for which current treatments are ineffective, expensive, and toxic.

Open Access Initiative Reveals Drug Hits For Deadly Neglected Tropical Diseases

Press Release | Drugs for Neglected Diseases initiative (DNDi), Medicines for Malaria Venture (MMV) | November 13, 2012

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through DNDi’s screening of MMV’s open access Malaria Box. Read More »

Recent Research Highlights Potential Of Open Access In Drug Discovery

Rachel Marusak Hermann | Intellectual Property Watch | November 14, 2012

The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announced the identification of three potential drug classes for the treatment of neglected tropical diseases through the availability of hundreds of compounds in the public domain. Read More »

The Opposite of Martin Shkreli: Drug Development Without Profit

Amy Maxmen | Global Health Now | December 14, 2015

From inside the van, Nathalie Strub Wourgaft watches the scene unfold in silence. She looks tired, and a little tense. Wourgaft is the medical director of a Geneva-based organization devoted to developing treatments for syndromes that afflict the poor, called the Drugs for Neglected Diseases initiative (DNDi), and she is in Sudan for just 3 days to scope out the setting for a clinical trial that will be the first of its kind. By May, Wourgaft and a Sudanese surgeon, Ahmed Fahal, hope to test a new drug for a potentially lethal, flesh-eating fungal infection called mycetoma...

Read More »